HCW Biologics Inc.
No enriched coverage for $HCWB in the last 7 days.
No SEC Form 4 filings for $HCWB in the last 30 days.
See all $HCWB insider activity →HCW Biologics (HCWB) priced a $1.5M private placement with an existing stockholder, issuing 903,614 units. Each unit includes a pre-funded warrant and a common warrant, subject to stockholder approval. Proceeds will fund clinical trials and general corporate purposes. HCWB stock closed at $1.66, down 8.29%, and was up 1.61% in pre-market trading.
HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Inc. Announces Pricing of $1.5 Million Private Placement MIRAMAR, Fla., September 24, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fus
HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the s
Recent HCWB coverage spans corporate actions, earnings and insider activity.
The capital raise provides cash for clinical trials and may modestly support the stock.
The modest capital raise provides short‑term funding for ongoing trials but is unlikely to move the stock significantly.
The partnership could expand market reach for HCW11‑006, potentially boosting revenue and stock valuation.
Early clinical signals plus FDA regulatory engagement can support a positive re-rating, especially for small-cap biotech momentum.
Going-concern language plus wider losses increases near-term financing and dilution risk, while Phase 1 readout timing offers a potential catalyst.
AlphAI scores every news story that mentions HCWB with an AI model for sentiment and relevance, and aggregates insider trades from HCW Biologics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HCW Biologics (HCWB) priced a $1.5M private placement with an existing stockholder, issuing 903,614 units. Each unit includes a pre-funded warrant and a common warrant, subject to stockholder approval. Proceeds will fund clinical trials and general corporate purposes. HCWB stock closed at $1.66, down 8.29%, and was up 1.61% in pre-market trading.
1 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Inc. Announces Pricing of $1.5 Million Private Placement MIRAMAR, Fla., September 24, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fus
1 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the s
2 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min readHCW Biologics (HCWB) reported a wider Q2 net loss of $5.2 million versus $1.9 million a year earlier, with licensing revenue rising to $135,568 from $6,550. The company said there is substantial doubt about continuing as a going concern without additional funding. It expects Phase 1 data for HCW9302 in alopecia areata in Q4 2026.
3 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results Miramar, FL – August 14, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on de
6 min readWong Hing C (Chief Executive Officer) purchased 23,210 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
2 min readFlowers Lee (SVP of Business Development) purchased 7,736 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
1 min readHCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative
6 min readHCW Biologics Inc. (NASDAQ: HCWB) priced a $1.6 million private placement, issuing 618,682 units at $2.585 per unit. Each unit includes one common share (or a pre-funded warrant) and a common warrant, subject to stockholder approval. Net proceeds will fund clinical trials for HCW9302 and IND-enabling work for HCW11-018b and HCW11-040.
3 min read
